Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Teprotumumab (Primary)
- Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Hepatic tumours; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- 17 Jan 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.